Clinical Trials
14 trialsNCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT05643690 2024-06-06
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
AnchorDx Medical Co. Ltd. US
Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT05361915 2024-03-18
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Sorrento Therapeutics, Inc.
Phase 2 Suspended
NCT04053062 2024-01-05
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Bioray Laboratories
Phase 1 Suspended
NCT03236688 2022-10-06
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Exosome Diagnostics, Inc.
Suspended
NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
NCT03734575 2019-07-11
ClariCore System Used in Transperineal Prostate Biopsy
Precision Biopsy, Inc.
Phase NA Suspended
NCT01337518 2012-12-18
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Enzon Pharmaceuticals, Inc.
Phase 1 Suspended
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00065572 2011-01-26
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
AstraZeneca
Phase 2 Suspended
NCT00909558 2010-02-24
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
Phase 1 Suspended
NCT00103623 2006-09-19
The Plenaxis® Experience Study
PRAECIS Pharmaceuticals Inc.
Phase 4 Suspended
NCT00033956 2005-06-24
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
MetaPhore Pharmaceuticals
Phase 1/2 Suspended